Dear [Name],

Please allow me to thank you for your time and drive in the recent discussions CureVac had with the European Commission on the development of our SARS-CoV-2 vaccine.

In these discussions, the Company... This letter aims at detailing the

1. As previously discussed, the CureVac is moving into... The demand and competition for those.

The Company is...

In exchange, CureVac...

While many variables...
This dose range is based on the Company's preclinical results showing very high neutralization with its optimized mRNA construct. In contrast, Moderna announced that it will test doses of 50μg and 100μg.

The Company is ready to...

Of note, recent publications of OXFORD results or the Chinese Beijing institute on adenovirus do not show promising results in humans and demonstrate that adjuvanted-proteins and mRNA are more promising technologies, inducing high neutralization titers.

2.

Assuming the optimum dose determined in the clinical trial is this...

In the short run, CureVac will present the vaccine in...

Additional discussions

In our recent exchanges, we were referring to the...
I trust this properly summarises the situation we have all discussed and formalises the

I am looking forward to exchanging at your earliest convenience,

Yours Sincerely,